These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31638195)

  • 1. Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia.
    Bernardi S; Foroni C; Zanaglio C; Re F; Polverelli N; Turra A; Morello E; Farina M; Cattina F; Gandolfi L; Zollner T; Buttini EA; Malagola M; Russo D
    Int J Mol Med; 2019 Dec; 44(6):2133-2144. PubMed ID: 31638195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib.
    Hrdinova T; Toman O; Dresler J; Klimentova J; Salovska B; Pajer P; Bartos O; Polivkova V; Linhartova J; Machova Polakova K; Kabickova H; Brodska B; Krijt M; Zivny J; Vyoral D; Petrak J
    Int J Oncol; 2021 Feb; 58(2):238-250. PubMed ID: 33491750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomes derived from imatinib-resistant chronic myeloid leukemia cells mediate a horizontal transfer of drug-resistant trait by delivering miR-365.
    Min QH; Wang XZ; Zhang J; Chen QG; Li SQ; Liu XQ; Li J; Liu J; Yang WM; Jiang YH; Xu YM; Lin J; Gao QF; Sun F; Zhang L; Huang B
    Exp Cell Res; 2018 Jan; 362(2):386-393. PubMed ID: 29223442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
    Luatti S; Baldazzi C; Marzocchi G; Ameli G; Bochicchio MT; Soverini S; Castagnetti F; Tiribelli M; Gugliotta G; Martinelli G; Baccarani M; Cavo M; Rosti G; Testoni N
    Oncotarget; 2017 May; 8(18):29906-29913. PubMed ID: 28404889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism.
    Raimondo S; Saieva L; Corrado C; Fontana S; Flugy A; Rizzo A; De Leo G; Alessandro R
    Cell Commun Signal; 2015 Feb; 13():8. PubMed ID: 25644060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
    Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
    Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic Myeloid Leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation.
    Soliman DS; Amer AM; Mudawi D; Al-Sabbagh Z; Alkuwari E; Al-Sabbagh A; Ibrahim F; Yassin MA
    Acta Biomed; 2018 Apr; 89(3-S):38-44. PubMed ID: 29633732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
    Danisz K; Blasiak J
    Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
    Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
    Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy.
    Massaro F; Colafigli G; Molica M; Breccia M
    Expert Rev Hematol; 2018 Apr; 11(4):301-306. PubMed ID: 29522367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
    Ercaliskan A; Eskazan AE
    Cancer; 2018 Oct; 124(19):3806-3818. PubMed ID: 29694669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.